Home LiteratureArticle Details
PMID: 22025274 Published · ppublish English Journal Article Review

Influenza neuraminidase: a druggable target for natural products.

Natural product reports ·Vol. 29 ·No. 1 ·2012-01-00 ·Pages 11-36

Grienke U, Schmidtke M, von Grafenstein S, Kirchmair J, Liedl KR, Rollinger JM

Abstract

The imminent threat of influenza pandemics and repeatedly reported emergence of new drug-resistant influenza virus strains demonstrate the urgent need for developing innovative and effective antiviral agents for prevention and treatment. At present, influenza neuraminidase (NA), a key enzyme in viral replication, spread, and pathogenesis, is considered to be one of the most promising targets for combating influenza. Despite the substantial medical potential of NA inhibitors (NAIs), only three of these drugs are currently on the market (zanamivir, oseltamivir, and peramivir). Moreover, sudden changes in NAI susceptibility revealed the urgent need in the discovery/identification of novel inhibitors. Nature offers an abundance of biosynthesized compounds comprising chemical scaffolds of high diversity, which present an infinite pool of chemical entities for target-oriented drug discovery in the battle against this highly contagious pathogen. This review illuminates the increasing research efforts of the past decade (2000-2011), focusing on the structure, function and druggability of influenza NA, as well as its inhibition by natural products. Following a critical discussion of publications describing some 150 secondary plant metabolites tested for their inhibitory potential against influenza NA, the impact of three different strategies to identify and develop novel NAIs is presented: (i) bioactivity screening of herbal extracts, (ii) exploitation of empirical knowledge, and (iii) computational approaches. This work addresses the latest developments in theoretical and experimental research on properties of NA that are and will be driving anti-influenza drug development now and in the near future.

MeSH Terms
Antiviral Agents/chemistry,pharmacology Biological Products/chemistry,pharmacology Enzyme Inhibitors/chemistry,pharmacology Humans Influenza A Virus, H1N1 Subtype/drug effects Influenza Vaccines/pharmacology Influenza, Human/classification,drug therapy Molecular Structure Neuraminidase/antagonists & inhibitors,chemistry,drug effects Terpenes/chemistry,pharmacology
Chemicals
Antiviral Agents Biological Products Enzyme Inhibitors Influenza Vaccines Terpenes Neuraminidase
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Grienke Ulrike
Institute of Pharmacy/Pharmacognosy and Center for Molecular Biosciences Innsbruck, University of Innsbruck, Austria.
Schmidtke Michaela
von Grafenstein Susanne
Kirchmair Johannes
Liedl Klaus R
Rollinger Judith M
Article Info
Journal
Natural product reports
Abbr.
Nat Prod Rep
ISSN
1460-4752
Published
2012-01-00
Epub
2011-00-25
Pages
11-36
Language
English
Region
England
NLM ID
8502408
Subset
IM
Grants
Austrian Science Fund FWF · P 24587 · Austria
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com